Chemed (FRA:CXM) 5-Year Yield-on-Cost %: 0.79 (As of Jul. 12, 2026) — 61% Above Median


FRA:CXM Chemed Corp FRA:CXM
78 GF Score
Price €424.00
GF Value €572.53
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Chemed 5-Year Yield-on-Cost %?

Chemed FRA:CXM +1.92% 78 5-Year Yield-on-Cost % is 0.79 as of Jul. 12, 2026, which is 61% above its 10-year median of 0.49. GuruFocus rates FRA:CXM with a GF Score™ of 78/100 and a GF Value™ of €572.53 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 281 Healthcare Providers & Services companies, Chemed ranks worse than 83.27% on this metric.

Chemed's yield on cost for the quarter that ended in Mar. 2026 was 0.79.


The historical rank and industry rank for Chemed's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:CXM' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.39   Med: 0.49   Max: 1.2
Current: 0.79


During the past 13 years, Chemed's highest Yield on Cost was 1.20. The lowest was 0.39. And the median was 0.49.


FRA:CXM's 5-Year Yield-on-Cost % is ranked worse than
83.27% of 281 companies
in the Healthcare Providers & Services industry
Industry Median: 2.92 vs FRA:CXM: 0.79

Chemed  (FRA:CXM) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Chemed 5-Year Yield-on-Cost % Related Terms


FRA:CXM vs PACS, LFST, CON: 5-Year Yield-on-Cost % Comparison

For the Medical Care Facilities subindustry, Chemed's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chemed 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Chemed's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Chemed's 5-Year Yield-on-Cost % falls into.


FRA:CXM
78GF Score
Chemed Corp FRA:CXM
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemed 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Chemed is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.79 mean?
Chemed (FRA:CXM) has a 5-Year Yield-on-Cost % of 0.79 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chemed and its competitors. This is 61% above median its historical median of 0.49. Over the past decade, Chemed's 5-Year Yield-on-Cost % has ranged from 0.39 to 1.20. According to the industry distribution chart, Chemed ranks #234 out of 281 companies in the Healthcare Providers & Services industry, placing it in the top 83.3%.
Is Chemed's 5-Year Yield-on-Cost % too high?
Chemed's current 5-Year Yield-on-Cost % of 0.79 is 61% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.39 to a high of 1.20. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.92. Chemed's value of 0.79 is 72.9% below this industry median. Based on the distribution chart, Chemed ranks #234 out of 281 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Chemed has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chemed's 5-Year Yield-on-Cost % compare to PACS and LFST?
According to the Healthcare Providers & Services industry distribution chart, Chemed ranks #234 out of 281 companies for 5-Year Yield-on-Cost %. This places Chemed in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.92. Chemed's value of 0.79 is 72.9% below this benchmark. Historically, Chemed's own 5-Year Yield-on-Cost % has ranged from 0.39 to 1.20 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 2.92, Chemed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.92, based on 281 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemed's current 5-Year Yield-on-Cost % of 0.79 is 72.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chemed and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemed's current 5-Year Yield-on-Cost % is 0.79, which is 61% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemed stock overvalued right now?
Based on GuruFocus' analysis, Chemed (FRA:CXM) is currently considered Modestly Undervalued. The stock's GF Value™ is €572.53, compared to a current price of €424.00 — trading 25.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.79, which is 61% above median its 10-year median of 0.49 and 72.9% below the Healthcare Providers & Services industry median of 2.92. Chemed's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chemed (FRA:CXM), the current 5-Year Yield-on-Cost % is 0.79 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chemed (FRA:CXM) Overvalued in 2026?

Based on GuruFocus' analysis, Chemed stock appears to be undervalued. The current stock price of €424.00 is trading 25.9% below its estimated GF Value™ of €572.53. GuruFocus considers Chemed to be Modestly Undervalued.

Key valuation signals for FRA:CXM:

  • 5-Year Yield-on-Cost %: 0.79 (61% above median its 10-year median of 0.49)
  • GF Value™: €572.53 vs. price of €424.00 (25.9% below fair value)
  • GF Score™: 78/100 with 6 warning signs
  • Industry Position: 72.9% below the Healthcare Providers & Services median (#234 of 281)

No single metric tells the full story. See the FRA:CXM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chemed Business Description

Other Exchanges CHE:USA
Address 255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
78GF Score

Get the complete analysis for FRA:CXM

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€424.00
Price
€572.53
GF Value